What Neobiomics does

Neobiomics AB is a Swedish life-science company founded in 2016 and headquartered in Solna (Stockholm), focused exclusively on neonatal nutrition for preterm infants. The company commercializes two clinically formulated products: ProPrems®, a three-strain probiotic dietary supplement (Bifidobacterium infantis Bb-02, Bifidobacterium lactis BB-12®, Streptococcus thermophilus TH-4®) launched in 2019 and packaged in single-dose format with a 24-month shelf life; and NeoMega36®, a food for medical purposes launched in 2023 that delivers ARA and DHA in a 2:1 ratio aligned with ESPGHAN recommendations to support visual development in preterm infants. Both products are manufactured under GMP (21 CFR part 111) and HACCP European food law compliance and are notified in multiple European jurisdictions.

The company sells primarily to neonatal intensive care units (NICUs), hospitals, and healthcare professionals (neonatologists, dietitians, midwives) through a hybrid go-to-market combining exclusive regional distribution partnerships (ExCEEd Orphan in CEE, Ewopharma in Switzerland, BIOS Therapeutics in Greece, KH Medicals in Qatar), direct regional field sales in the UK and Italy, and a transactional e-commerce storefront on neobiomics.eu. Pricing is not publicly disclosed; quotes are issued on request for institutional buyers, and revenue is generated through one-time product sales settled via Stripe or PayPal/Braintree. The company claims 170+ collaborating centres and 100+ hospitals across more than 15 countries, with 5,000+ distributed portions of ProPrems® by March 2020.

Neobiomics is affiliated with Karolinska Institutet Innovations AB, founded by a Consultant Neonatologist/Associate Professor (Stefan Johansson) and a veterinary/pharmaceutical medicine doctor (Philipp Novak), and is backed by life-sciences VC HealthCap (investment May 2026, board seat held by Managing Partner Mårten Steen). Following the February 2024 appointment of Emma Höglund, formerly of MSD/Merck & Co, Novartis, and BCB Medical, as CEO, the leadership team has shifted toward commercial scaling, supported by roughly a dozen staff across sales, product management, customer support, and scientific affairs.

Name

Neobiomics

Legal name

Neobiomics AB

Website

https://neobiomics.eu

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Neobiomics is a Swedish life-science company that develops and sells clinically formulated dietary supplements — ProPrems® (probiotic blend) and NeoMega36® (ARA/DHA medical food) — to NICUs and hospitals for preterm infant nutrition across Europe and the Middle East.

Ownership category

akta.pro rank

Product category

Neonatal Nutrition Supplements

NAICS

Food Manufacturing (311)

SIC

Food And Kindred Products (2000)

akta.pro primary industry

Special Medical Purpose Infant Formula Manufacturing (FSMP/Medical Nutrition) (AFAHAHAC)

akta.pro secondary industries

Baby Feeding Supplements & Fortifiers (Probiotics, DHA/ARA, Vitamins) (CRADAEAI), Baby Nutrition for Special Diets (Gluten-Free, Kosher/Halal, Allergen-Controlled) (CRADAEAO)

Keywords

• Preterm infant nutrition
• Neonatal dietary supplements
• Probiotic supplements
• Clinical nutrition products
• Infant formula manufacturing

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Product Sales - Dietary Supplements: Neobiomics generates revenue through the sale of its proprietary dietary supplement products (ProPrems® and NeoMega36®) directly to hospitals, healthcare facilities, and through distribution partners across Europe. The company uses third-party payment processors (Stripe, PayPal/Braintree) for transaction processing.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Core offering

Neobiomics develops, manufactures, and sells clinically-formulated dietary supplements specifically designed for preterm infants. The company's core product line comprises ProPrems®, a proprietary 3-strain probiotic blend for gut health support, and NeoMega36®, an ARA/DHA fatty acid food for medical purposes supporting normal vision development. Products are manufactured under GMP and HACCP standards and sold primarily to neonatal intensive care units (NICUs), hospitals, and healthcare professionals across Europe through direct sales and exclusive regional distribution partners.

Product overview

Neobiomics is a Swedish dietary supplement company offering two core products for neonatal care. ProPrems® is the foundational product launched in 2019 — a probiotic blend of three bacterial strains for preterm infants. NeoMega36® is a newer product (2023) designed as a food for special medical purposes enriched with ARA and DHA fatty acids for normal vision development in preterm infants. Both products target the neonatal/preterm care market and are distributed through hospital collaborations across Europe.

Differentiator

Problem solved

Functional benefit

Brands

• ProPrems®: A high-quality dietary supplement containing a blend of 3 bacterial strains (Bifidobacterium infantis Bb-02, Bifidobacterium lactis BB-12®, Streptococcus thermophilus TH-4®) for infants. ProPrems has been collaborating with 170+ centres across Europe since 2019.
• NeoMega36®

Products and services

• ProPrems® ProPrems® is a high-quality food supplement (probiotic blend) containing three bacterial strains — Bifidobacterium infantis Bb-02, Bifidobacterium lactis BB-12®, and Streptococcus thermophilus TH-4® — designed for neonatal care. It is packed in single-dosage format, has a 24-month shelf life, and is manufactured under GMP (21 CFR part 111) and HACCP European food law compliance. It is intended for preterm infants to support gut health and is sold to hospitals, NICUs, and neonatology clinicians across Europe.
• NeoMega36® NeoMega36® is a food for medical purposes (food supplement) enriched with ARA (arachidonic acid) and DHA (docosahexaenoic acid) tailored for preterm infants. It delivers ARA at 100 mg/kg/d and DHA at 50 mg/kg/d in a 2:1 ratio matching breast milk composition, aligned with ESPGHAN recommendations. It is notified in Sweden, Norway, Germany, the Netherlands, Switzerland, Austria, Iceland, Finland, Czech Republic, Slovenia, Slovakia, and Hungary, and supports the normal development of vision function in preterm infants.

Quantifiable outcome

• 100+ hospitals using ProPrems® as of November 2022
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature3 records

Partnerships

Six partnerships are on record, tiered regional and core.

• KH MedicalsregionalChannel Partner/ Reseller/ Distributor · 10 October 2023Neobiomics and KH Medicals collaborated for the distribution of ProPrems® in Qatar. This partnership extends Neobiomics' presence to the Middle East market.
• BIOS THERAPEUTICSregionalChannel Partner/ Reseller/ Distributor · 21 July 2023Exclusive collaboration for the distribution of ProPrems® in Greece. BIOS THERAPEUTICS serves as the exclusive distributor for the Greek market.
• ExCEEd Orphan s.r.o.regionalChannel Partner/ Reseller/ Distributor · 1 February 2022First sales of ProPrems® in the Czech Republic and Hungary through ExCEEd Orphan partnership. The partnership expanded to Central and Eastern Europe region.
• ExCEEd Orphan s.r.o.regionalChannel Partner/ Reseller/ Distributor · 21 May 2021Exclusive cooperation agreement for distribution of ProPrems® in Central and Eastern Europe (initially Czech Republic and Hungary).
• Ewopharma AGregionalChannel Partner/ Reseller/ Distributor · 17 May 2021Exclusive collaboration for distribution of ProPrems® in Switzerland. Ewopharma AG serves as the exclusive distributor for the Swiss market.
• Karolinska Institutet Innovations ABcoreStrategic or Co-development PartnerNeobiomics is affiliated with Karolinska Institutet Innovations AB, Stockholm. The company was founded based on research from Karolinska Institutet, and co-founder Stefan Johansson holds an Associate Professor position and PhD at Karolinska Institutet.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Nestlé Health Science: Medical nutrition arm of Nestlé offering preterm and pediatric nutrition products across global markets. Directly comparable category overlap with Neobiomics' neonatal focus, but as a broad incumbent rather than a niche specialist.
• Mead Johnson Nutrition (Reckitt): Long-established infant formula brand (Enfamil) with preterm and specialty pediatric lines. Overlaps with Neobiomics in NICU feeding, but at much larger scale and as part of Reckitt's broader nutrition portfolio.
• Nutricia (Danone): Global leader in medical nutrition with a dedicated preterm and neonatal nutrition portfolio (e.g., preterm formula and human milk fortifiers). Comparable in serving NICUs with specialized nutrition, but operates at much larger scale and across many therapeutic areas.
• Abbott Nutrition: Major infant nutrition manufacturer with specialty preterm and post-discharge formulas (e.g., Similac NeoSure). Comparable in serving preterm infants with specialized nutrition, but operates as a global incumbent with broad product breadth.

Others

• Chr. Hansen: Global bioscience company producing probiotic strains including BB-12, which Neobiomics uses in ProPrems. Functions as a supplier/enabler in the same value chain rather than a competitor, but its probiotic portfolio targets adjacent infant nutrition applications.

Regional players

• Semper: Swedish pediatric and infant nutrition company (part of Hero Group) with a long presence in Nordic hospitals. Comparable in Swedish origin and pediatric nutrition focus, though with broader product breadth and different distribution model.
• Hero Nutritional Products: European pediatric nutrition company (parent of Semper) offering infant and specialty nutrition. Comparable in serving neonatal and pediatric nutritional needs across European markets, with broader consumer and medical nutrition portfolio.
• HiPP: German family-owned infant nutrition company with organic and specialty formula lines including preterm options. Comparable product category and European market overlap, though with broader consumer-grade positioning.

Direct peers

• BioGaia: Swedish probiotics company with a portfolio of Lactobacillus and Bifidobacterium strains, including pediatric and infant products. Direct overlap with Neobiomics in probiotic supplementation for infants, including shared use of clinically documented strains and similar NICU/neonatology positioning.

Emerging players

• Prolacta Bioscience: US-based specialty nutrition company focused on human milk-based products for premature infants in NICUs. Directly comparable focus on preterm neonatal nutrition, though concentrated in the US market with a different product modality.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/neobiomics
• Facebookfacebook.com/neobiomics
• LinkedInlinkedin.com/company/neobiomics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neobiomics